Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lessened its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 12.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 324,251 shares of the biotechnology company’s stock after selling 48,031 shares during the quarter. Nordea Investment Management AB’s holdings in Arrowhead Pharmaceuticals were worth $21,566,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at about $29,000. Virtus Advisers LLC bought a new stake in Arrowhead Pharmaceuticals in the second quarter worth about $34,000. Salomon & Ludwin LLC bought a new stake in Arrowhead Pharmaceuticals in the third quarter worth about $34,000. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,618 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ARWR. The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Chardan Capital upped their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $56.27 on Wednesday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76. The firm has a market capitalization of $7.88 billion, a PE ratio of 36.78 and a beta of 1.23. The firm has a 50-day moving average of $63.20 and a two-hundred day moving average of $53.12.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. During the same period last year, the business earned ($1.39) earnings per share. The business’s revenue was up 10461.3% on a year-over-year basis. On average, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 7,530 shares of the business’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the sale, the director directly owned 69,053 shares of the company’s stock, valued at $4,833,710. The trade was a 9.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider owned 171,958 shares of the company’s stock, valued at $10,852,269.38. The trade was a 18.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 172,100 shares of company stock worth $11,274,732. Company insiders own 3.60% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.